Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.47 |
| ▸ | RXRA | P19793 | 7/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756468 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL6523576 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL25756467 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL3724868 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL6523965 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL24451647 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL3664778 | 0.89 | NR1H2 (0.51) | BACE1NR1H2NR1H3RXRA | |
| SCHEMBL25240372 | 0.89 | NR1H2 (0.51) | BACE1NR1H2NR1H3RXRA | |
| SCHEMBL6521416 | 0.89 | NR1H2 (0.51) | BACE1NR1H2NR1H3RXRA | |
| SCHEMBL26312430 | 0.89 | NR1H2 (0.48) | BACE1NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| WO-2023109926-A1 | SPIROOXINDOLE COMPOUND AND USE THEREOF IN PREPARATION OF PROTEASE INHIBITOR AS ANTIVIRAL DRUG | 南京药石科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230103494-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022109363-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-4001279-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103494-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | BACE1 3739/4885NR1H2 460/4885NR1H3 445/4885 |
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ACE2, NR3C2, ACE | BACE1 2956/4885NR1H2 87/4885NR1H3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.